stable triple alpha helical coiled coil complex with two other

TTSEs, [with the proviso that] where (a) the heterologous moiety

is different from any of the fusion proteins CIIH6FXTN123,

H6FXTN123, H6FXTN12M H6FCTN23, the sequences of which are shown in

SEQ ID NOs:24-27[.]; and/or (b) at least one heterologous moiety

being one in which does not exclusively facilitate expression

and/or purification of the monomer polypeptide construct.

2 (amended). [A] The monomer polypeptide construct

[comprising at least one tetranectin trimerising structural

element (TTSE) which is covalently linked to at least one

heterologous moiety, said TTSE being capable of forming a stable

triple alpha helical coiled coil complex with two other TTSEs,

said at least one heterologous moiety being one which does not

exclusively facilitate expression and/or purification of the

monomer polypeptide construct] of claim 1 where (a) applies. --

Claim 3, line 1, replace "A" with --The--; and

line 1, replace "any of the preceding claims"

with --claim 1--.

Claim 4, line 1, replace "A" with --The--; and

line 1, replace "any of the preceding claims"

with --claim 1--.

Claim 5, line 1, replace "A" with --The--.

Claim 6, line 1, replace "A" with --The--; and

line 1, delete "or 5".

Claim 7, line 1, replace "A" with --The--; and

line 1, replace "any of claims 1-3" with

2

--claim 1--.

Claim 8, line 1, replace "A" with --The--; and

line 1, replace "any of the preceding claims"

with --claim 1--.

Claim 9, line 1, replace "A" with --The--.

Claim 10, line 1, replace "A" with --The--; and

line 2, delete "such as at least 81%m at least

87%, or at least 92%".

Claim 11, line 1, replace "A" with --The--; and

line 1, replace "any of claims 8-10" with

--claim 8--.

Claim 12, line 1, replace "A" with --The--; and

line 1, replace "any of the preceding claims"

with --claim 1--.

Claim 13, line 1, replace "A" with --The--.

Claim 14, line 1, replace "A" with --The--; and

line 1, replace "any of the preceding claims"

with --claim 1--.

Claim 15, line 1, replace "A" with --The--; and

line 1, replace "any of the preceding claims"

with --claim 1--.

Claim 16, line 1, replace "A" with --The--; and

line 1, replace "any of the preceding claims"

with --claim 1--.

Claim 17, line 1, replace "A" with --The--; and

line 1, replace "any of the preceding claims" with --claim 1--.

Claim 18, line 1, replace "A" with --The--; and

line 1, replace "any of the preceding claims" with --claim 1--.

-- 19 (amended). An oligomer [which is comprised of] comprising at least two monomer polypeptide constructs according to [any of claims 1-18 and which comprises at least three TTSE's or a multiplum of three TTSE's, or which is comprised of three monomer polypeptide constructs according to any of claims 1-3 or 7-18] claim 1. --

Claim 21, line 1, delete "or 20".

Claim 24, line 1, replace "any of claims 19-23" with --claim 19--.

Claim 25, line 1, replace "any of claims 1-18" with --claim 1--.

Claim 26, line 1, delete "according to claim 19";

line 2, replace "any of claims 1-18" with --claim 1--; and

lines 3 and 4, replace "any of claims 1-3 or 7-18" with --claim 1--.

Claim 27, line 1, delete "according to claim 19"; and

line 2, replace "any of claims 1-18" with --claim 1--.

Claim 28, line 3, replace "any of claims 1-18" with --claim 1--;

4

lines 5 and 6, replace "any of claims 1-18" with --claim 1--; and

lines 9 and 10, replace "any of claims 1-3 or 7-18" with --claim 1--.

Claim 30, line 1, delete "or 29".

Claim 31, line 1, replace "any of claims 1-18" with --claim 1--; and

lines 2 and 3, replace "any of claims 1-18" with --claim 1--.

Delete claim 34 in its entirety.

Claim 35, line 1, replace "use" with --method--; and

line 1, replace "34" with --65--; and

line 1, replace "moity" with --moiety--.

-- 36 (amended). [The use of a monomer polypeptide construct according to any of claims 1-18 or to a an oligomer according to any of claims 9-24 as a] A component of a chimaeric product having low antigenicity in humans relative to formulations comprising on<u>e</u> or more components of non-human origin<u>, and</u> <u>comprising at least one monomer polypeptide construct according to</u> <u>claim 1</u>.

37 (amended). [The use] <u>In a method</u> of [a monomer polypeptide construct according to any of claims 1-18 or to a an oligomer according to any of claims 19-24 as a vehicle for] assembling antibody fragments into oligometric or multivalent entities for generating chimeric artificial antibodies having preselected pharmacokinetic and/or pharmadynamic properties <u>the</u>

5

improvement which comprises use of at least one monomer polypeptide construct according to claim 1 as a vehicle.

A4 cncld.

38 (amended). The [use] method of claim 48 comprising [a monomer polypeptide construct according to any of claims 1-18 or to a an oligomer according to any of claims 19-24 for] delivering an imaging or toxin-conjugated antibody to a tumor.

39 (amended). [The use of a monomer polypeptide construct according to any of claims 1-18 or to a oligomer according to any of claims 19-24 as a vehicle delivering an] In a method of delivering a substance to a target cell or tissue, the improvement which comprises use of a conjugate of said substance and at least one monomeric polypeptide construct according to claim 1. --

Delete claims 40-46 in their entirety.

A5 cm.t

-- 47 (amended). [The use according to any of claims 34 to 46 wherein the] A composition comprising at least one monomer polypeptide construct according to claim 1 [any of claims 1-18 or the oligomer according to any of claims 19-21 is comprised] in a liposome.

48 (amended). A method for treating or preventing a disease comprising administering to [the] a subject in need thereof a therapeutically or prophylactically effective amount of a [an effective amount of a pharmaceutical composition as defined in any of claims 44 and 45] pharmaceutically acceptable composition comprising

(a) a pharmaceutical comprising at least one monomer

polypeptide construct according to claim 1, or

(b) a gene therapy vector comprising DNA encoding a pharmaceutical of (a) above.

Delete claims 49 and 50 in their entirety.

Claim 51, lines 1 and 2, replace "A method of human gene therapy comprising use of a monomer polypeptide construct according to any of claims 1-18 or to an oligomer according to any of claims 19-24" with --The method of claim 65--.

Claim 52, line 1, replace "A" with --The--;

line 1, replace "any of claims 48 to 51" with

--claim 48--;

lines 2 and 3, replace "monomer polypeptide construct according to any of claims 1-18 or the oligomer according to any of claims 19-24" with --composition--; and

line 6, delete "such as a tumour".

Delete claim 53 in its entirety.

-- 54 (amended). A method for diagnosis of a disease comprising a [construct comprising the monomer polypeptide construct according to any of claims 1-18 or the oligomer according to any of claims 19-24 together with a diagnosing component coupled thereon] contacting a sample with a diagnostic agent according to claim 66, and correlating the degree of interaction between the agent and the sample, with the status of the disease. --

Please add the following claims:

-- 55. The monomer polypeptide construct of claim 1

7

where (b) applies.

56. The monomer polypeptide construct of claim 2 where (b) applies.

57. The monomer polypeptide construct of claim 1 which comprises a plurality of TTSEs.

58. The monomer polypeptide construct of claim 1 which comprises at least three TTSEs.

59. The monomer polypeptide construct of claim 1 which has exactly an integer ($\geq$1) multiple of three TTSEs.

60. The oligomer of claim 24, comprising at least three monomer polypeptide constructs.

61. An oligomer comprising at least two monomer polypeptide constructs according to claim 59.

62. The method of claim 48 in which the pharmaceutical is a monomer polypeptide construct.

63. The method of claim 48 in which the pharmaceutical is an oligomer comprising at least two mononomer polypeptide constructs.

64. The method of claim 48 in which (a) is administered.

65. The method of claim 48 in which (b) is administered.

66. A diagnostic agent comprising at least one monomer polypeptide construct according to claim 1, and a detectable label or an insoluble support.

67. In a method of displaying a protein library the

8